Figure 4
Figure 4. RvE1 is a potent inhibitor of human platelet aggregation in PRP. PRP collected from healthy donors was incubated with RvE1 (15 minutes, 37°C). denotes addition of ADP (10 μM; A), U46619 (0.5 μM; B), or collagen (1.5 μg/mL, C). Platelet aggregation was determined using an aggregometer. (D) RvE1 blocks ADP-induced platelet aggregation in a concentrationdependent fashion (representative of n = 6 donors). (E) Percentage inhibition of agonist-induced platelet aggregation by RvE1. ♦ indicates ADP (10 μM) plus RvE1 (n = 6 donors); ■, U46619 (0.5 μM) plus RvE1 (n = 6); and ▲, collagen (1.5 μg/mL) plus RvE1 (n = 4). Results are means plus or minus SEM. *P < .05; ***P < .001.

RvE1 is a potent inhibitor of human platelet aggregation in PRP. PRP collected from healthy donors was incubated with RvE1 (15 minutes, 37°C). denotes addition of ADP (10 μM; A), U46619 (0.5 μM; B), or collagen (1.5 μg/mL, C). Platelet aggregation was determined using an aggregometer. (D) RvE1 blocks ADP-induced platelet aggregation in a concentrationdependent fashion (representative of n = 6 donors). (E) Percentage inhibition of agonist-induced platelet aggregation by RvE1. ♦ indicates ADP (10 μM) plus RvE1 (n = 6 donors); ■, U46619 (0.5 μM) plus RvE1 (n = 6); and ▲, collagen (1.5 μg/mL) plus RvE1 (n = 4). Results are means plus or minus SEM. *P < .05; ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal